secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001558370-23-007566
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Bio Q1 WAKIX revenue $119.1M (+40% YoY); GAAP EPS $0.48; patients ~5,200
--------------------------------------------------------------------------------

- Net product revenue $119.1M, +39.6% YoY; GAAP net income $29.5M ($0.48 diluted EPS) vs $21.5M ($0.35) prior year.
- Average patients on WAKIX ~5,100 (+1,200 YoY); exited Q1 with ~5,200 patients.
- Cumulative WAKIX net revenue surpassed $1B since launch; Phase 3 IH INTUNE topline data expected Q4 2023.
- Non-GAAP adjusted net income $40.1M ($0.66 diluted EPS) vs $31.1M ($0.51) prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023007566/0001558370-23-007566-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837023007566/hrmy-20230502x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-007566

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer